SecBot SecBot
8-K ·Filed Nov 2, 2026

TCMD

TACTILE SYSTEMS TECHNOLOGY INC
MIXED
Impact 5/10
Horizonweeks Processed14d 10h ago SEC0001104659-26-121315
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The EPS miss and flat EBITDA vs prior year contrast with the strong lymphedema growth and raised EBITDA guidance. Watch for commentary on the airway clearance inventory normalization timeline and whether operating expense growth moderates in Q4 to deliver the raised EBITDA target.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$24.78
T+0 close · Nov 2, 2026 · via day close
Latest settled
+7.43%
T+5 · $26.62 · next T+20 in 15d
Vs SPY
+8.01%
α at T+5
Latest observation
+9.87%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $24.78entry
  2. T+1 · 13d ago +9.69%α +8.03% · $27.18
  3. T+5 · 7d ago +7.43%α +8.01% · $26.62
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tactile Medical reported Q3 2026 revenue of $91.9M (+7% YoY), slightly below the $92.0M consensus, and GAAP EPS of $0.31, below the $0.34 consensus. Net income declined to $7.2M from $8.2M a year ago, and Adjusted EBITDA was essentially flat at $14.3M. The company maintained its full-year revenue guidance of $360M-$366M but raised its Adjusted EBITDA guidance to $50M-$52M from $49M-$51M. The core lymphedema business grew 13% YoY, but airway clearance revenue fell 25% due to DME inventory transition, and operating expenses rose 13%.

Key Financial Metrics

EPS
$0.31
est $0.34 · -8.8%
Revenue
$91.9M
est $92.0M · -0.1% · +7.1% YoY
Rating
miss
Guidance
$360M-$366M
maintained
Gross Margin
76.7%

Key Facts

  • Q3 2026 total revenue $91.9M, up 7% YoY from $85.8M
  • GAAP diluted EPS $0.31 vs $0.36 in Q3 2025; consensus was $0.34
  • Net income $7.2M vs $8.2M in Q3 2025
  • Adjusted EBITDA $14.3M vs $14.4M in Q3 2025
  • Lymphedema product revenue $81.8M, up 13% YoY
  • Airway clearance product revenue $10.0M, down 25% YoY
  • Gross margin expanded to 77% from 76% in Q3 2025
  • Operating expenses increased 13% to $60.9M
  • Full-year 2026 revenue guidance maintained at $360M-$366M
  • Full-year 2026 Adjusted EBITDA guidance raised to $50M-$52M from $49M-$51M
  • Repurchased $6.2M of stock in Q3; $12.5M remaining under $25M buyback program
  • Cash balance $75.1M, no debt outstanding

Financial Impact

Revenue $91.9M, GAAP net income $7.2M, Adjusted EBITDA $14.3M; EPS miss of $0.03 vs consensus

revenueepsnet incomeadjusted EBITDAoperating expenses

Segment Breakdown

SegmentRevenueGrowth
Lymphedema products$81.8M+13.1%
Airway clearance products$10.0M-25.1%

Risk Factors

  • Airway clearance revenue declined 25% YoY due to DME inventory transition, with no clear recovery timeline
  • Operating expenses grew 13%, outpacing revenue growth of 7%, pressuring margins
  • Net income and EPS declined YoY despite revenue growth

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-121315
Document: tcmd-20261102x8k.htm0001104659-26-121315
Document: 0001104659-26-121315-index-headers.html0001104659-26-121315
Document: 0001104659-26-121315-index.html0001104659-26-121315
Document: 0001104659-26-121315.txt0001104659-26-121315
8-K Data (Synthetic)0001104659-26-121315

Track record

17 reports on TCMD

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $26.99 Now $26.37 −2.30% settles Feb 12
  2. Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $27.11 Now $26.37 −2.73% settles Feb 12
  3. Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $26.62 Now $26.37 −0.94% settles Feb 8
  4. Nov 6, 202610d ago 3 Neutral 2/10 Entry $26.59 Now $26.37 −0.83% settles Feb 5
  5. Nov 3, 202613d ago 144 Neutral 2/10 Entry $24.78 Now $26.37 +6.42% settles Feb 1
  6. Nov 2, 202614d ago 10-Q/A Neutral 2/10 Entry $24.78 Now $26.37 +6.42% settles Feb 1
  7. Nov 2, 202614d ago 10-Q/A Neutral 2/10 Entry $24.78 Now $26.37 +6.42% settles Feb 1
  8. Nov 2, 202614d ago Press Release Bearish 5/10 No price data
  9. Nov 2, 202614d ago 8-K Mixed 5/10 Viewing Entry $24.78 Now $26.37 +6.42% settles Feb 1
  10. Oct 19, 202628d ago Press Release Neutral 3/10 Entry $23.52 Now $26.37 +12.12% settles Jan 15
Showing 10 of 17

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026